Rxivist logo

A trimeric NTD and RBD SARS-CoV-2 subunit vaccine induced protective immunity in CAG-hACE2 transgenic mice and rhesus macaques

By Jiaping Yu, Wenrong Yao, Yingsong Hu, Shuang Wu, Jiao Li, Hongjun Zhou, Kunxue Hong, Jianping Chen, Longding Liu, Ke Lan, Feng-Cai Zhu, Yong Liu

Posted 05 Nov 2021
bioRxiv DOI: 10.1101/2021.11.03.467182

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to significant public health, economic and social problems. Development of effective vaccines is still a priority to contain the virus and end the global pandemic. In this study, we reported that ReCOV, a recombinant trimeric NTD and RBD two-component SARS-CoV-2 subunit vaccine adjuvanted with BFA03 (an AS03-like squalene adjuvant), induced high levels of neutralizing antibodies against SARS-CoV-2 and the circulating variants in mice, rabbits and rhesus macaques. Notably, two-dose immunizations of ReCOV provided complete protection against challenge with SARS-CoV-2 in hACE2 transgenic mice and rhesus macaques, without observable antibody-dependent enhancement of infection. These results support further clinical development of ReCOV and the vaccine is currently being evaluated in a phase I clinical trial in New Zealand (NCT04818801).

Download data

  • Downloaded 446 times
  • Download rankings, all-time:
    • Site-wide: 86,555
    • In immunology: 2,656
  • Year to date:
    • Site-wide: 4,780
  • Since beginning of last month:
    • Site-wide: 5,245

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide